Tp53 Gene Polymorphism (Rs1042522) in Rheumatoid Arthritis and Systemic Lupus Erythematosus: An Updated Systematic Review and Meta-Analysis Publisher Pubmed



Ebrahimiyan H^{1, 2} ; Madreseh E^{2, 3} ; Akhtari M⁴ ; Farhadi E^{2, 5} ; Jamshidi A² ; Mahmoudi M^{2, 5} Show Affiliations
Source: Current Rheumatology Reviews Published:2025

Abstract

Background: The p53 protein has important roles in apoptosis, proliferation, and prevention of DNA damage. Several studies have reported that TP53 gene polymorphism is associated with various autoimmune diseases, including Rheumatoid arthritis (RA) and Systemic lupus erythematosus (SLE). Objective: Evaluation of the correlation between TP53 gene rs1042522 polymorphism and RA and SLE risk by meta-analysis. Methods: Databases, including PubMed and Scopus, were searched to find studies assessing the association between TP53 gene polymorphism and RA and SLE risk in different populations up to August 2022. The protocol of this article was registered on the International Prospective Register Of Systematic Reviews (PROSPERO number: CRD42022309655). Results: Herein, 7 case-control studies, including 2498 cases and 3799 controls in the SLE group, and 6 case-control studies comprising 1593 cases and 4460 controls in the RA group that investigated rs1042522 SNP were included in the meta-analysis. Herein, CG genotypes were more frequent in healthy participants compared to SLE patients and may associated with a decreased SLE risk (OR=0.85, CI: 0.76-0.95, P-value <0.006). Besides, dominant and recessive models of CC+ CG vs. GG were also protective for SLE risk (OR=0.85, CI: 0.76-0.95, P-value <0.004). Conclusion: In summary, this study discloses a weak correlation between rs1042522 and a decreased risk of SLE. However, no significant association was found in RA. © 2024 Bentham Science Publishers.